QUEST for a cure for hepatitis C virus: the end is in sight.
作者信息
Ghany Marc G, Gara Naveen
机构信息
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1800, USA.
Department of Gastroenterology, Washington Hospital Center, Washington, DC, USA.
出版信息
Lancet. 2014 Aug 2;384(9941):381-3. doi: 10.1016/S0140-6736(14)60807-2. Epub 2014 Jun 4.
Abstract
摘要
相似文献
1
QUEST for a cure for hepatitis C virus: the end is in sight.寻求丙型肝炎病毒的治愈方法：曙光在望。
Lancet. 2014 Aug 2;384(9941):381-3. doi: 10.1016/S0140-6736(14)60807-2. Epub 2014 Jun 4.
2
Is the end of chronic hepatitis C virus infection in sight?丙型肝炎病毒慢性感染的终结在望吗？
Med J Aust. 2012 Jun 4;196(10):614. doi: 10.5694/mja12.10586.
3
Hepatitis C virus infection: when is a cure not a cure?丙型肝炎病毒感染：何时治愈并非真正治愈？
J Infect Dis. 2014 Jan 1;209(1):6-8. doi: 10.1093/infdis/jit543. Epub 2013 Oct 14.
4
Apparent cure of hepatitis C virus carrier state after hepatitis B virus superinfection.乙肝病毒重叠感染后丙型肝炎病毒携带状态的明显治愈
Jpn J Infect Dis. 1999 Oct;52(5):220.
5
Pioneering a Global Cure for Chronic Hepatitis C Virus Infection.开拓慢性丙型肝炎病毒感染全球治愈之路。
Cell. 2016 Sep 22;167(1):12-15. doi: 10.1016/j.cell.2016.08.038. Epub 2016 Sep 13.
6
Hepatitis C Virus is Treatable but We Need to Be Sure of a Cure.丙型肝炎病毒是可治疗的，但我们需要确保能将其治愈。
Isr Med Assoc J. 2021 Dec;23(12):819-820.
7
A cure for the high cost of hepatitis C virus treatment.丙型肝炎病毒治疗高昂费用的解决办法。
Ann Intern Med. 2015 May 5;162(9):660-1. doi: 10.7326/M15-0674.
8
Diagnosis and management of hepatitis C.丙型肝炎的诊断与管理
Br J Hosp Med (Lond). 2015 Nov;76(11):625-30. doi: 10.12968/hmed.2015.76.11.625.
9
Expanded hepatitis C virus screening recommendations promote opportunities for care and cure.扩大丙型肝炎病毒筛查建议为治疗和治愈创造了机会。
Ann Intern Med. 2013 Sep 3;159(5):364-5. doi: 10.7326/0003-4819-159-5-201309030-00675.
10
[Locked outside: cure of chronic hepatitis C using an entry inhibitor].[被拒之门外：使用一种进入抑制剂治愈慢性丙型肝炎]
Med Sci (Paris). 2015 Dec;31(12):1075-7. doi: 10.1051/medsci/20153112009. Epub 2015 Dec 16.
引用本文的文献
1
Applications of gold nanoparticles in virus detection.金纳米粒子在病毒检测中的应用。
Theranostics. 2018 Feb 15;8(7):1985-2017. doi: 10.7150/thno.23856. eCollection 2018.
2
Cancers in Australia in 2010 attributable to infectious agents.2010年澳大利亚归因于感染因子的癌症。
Aust N Z J Public Health. 2015 Oct;39(5):446-51. doi: 10.1111/1753-6405.12445.
3
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.丙型肝炎肝硬化：诊断与治疗的新视角
World J Hepatol. 2015 Jul 18;7(14):1843-55. doi: 10.4254/wjh.v7.i14.1843.
4
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.苏格兰队列中丙型肝炎病毒NS3治疗前耐药相关氨基酸变异的患病率。
J Clin Virol. 2015 Apr;65:50-3. doi: 10.1016/j.jcv.2015.02.005. Epub 2015 Feb 9.
本文引用的文献
1
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.西美瑞韦联合聚乙二醇干扰素 α-2a 和利巴韦林治疗初治慢性丙型肝炎病毒 1 型感染患者（QUEST-1）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4.
2
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.西美瑞韦联合聚乙二醇干扰素 α-2a 或 -2b 加利巴韦林治疗初治慢性丙型肝炎病毒基因 1 型感染患者（QUEST-2）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4.
3
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.来迪派韦索磷布韦片与索磷布韦联用治疗初治的 HCV 基因 1 型感染。
N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.
4
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.来迪派韦索磷布韦片治疗既往治疗的 HCV 基因 1 型感染。
N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.
5
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗肝硬化合并丙型肝炎。
N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
6
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和利巴韦林联合治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
7
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎
N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.
8
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
9
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.simeprevir 联合聚乙二醇干扰素和利巴韦林治疗既往治疗复发的 HCV 基因 1 型患者，可获得高 SVR 率：一项 3 期临床试验。
Gastroenterology. 2014 Jun;146(7):1669-79.e3. doi: 10.1053/j.gastro.2014.02.051. Epub 2014 Mar 3.
10
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.达卡他韦联合索非布韦治疗既往治疗或未经治疗的慢性 HCV 感染。
N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218.
Zotero 插件